KRAS Allelic Imbalance Strengths and Weaknesses in Numbers

Gary J Doherty, Emma M Kerr, Carla P Martins

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
354 Downloads (Pure)


The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable.

Original languageEnglish
Pages (from-to)377-378
JournalTrends in molecular medicine
Issue number5
Publication statusPublished - 31 Mar 2017
Externally publishedYes


  • Allelic Imbalance/genetics
  • Benzamides/pharmacology
  • Diphenylamine/analogs & derivatives
  • Gene Dosage/genetics
  • Humans
  • Leukemia/genetics
  • MAP Kinase Kinase 1/antagonists & inhibitors
  • MAP Kinase Kinase 2/antagonists & inhibitors
  • Models, Theoretical
  • Proto-Oncogene Proteins p21(ras)/genetics


Dive into the research topics of 'KRAS Allelic Imbalance Strengths and Weaknesses in Numbers'. Together they form a unique fingerprint.

Cite this